Eleven Biotherapeutics completes patient enrollment in dry eye study

Eleven Biotherapeutics has finished enrolling patients in its phase 3 clinical study of EBI-005 in patients with dry eye disease, the company announced.According to the press release, EBI-005 is a novel topical interleukin-1 receptor blocker and is currently being evaluated for the treatment of dry eye disease and allergic conjunctivitis.